A column in The Wall Street Journal discusses the difficulties involved with creating and marketing new trademarks in the pharmaceutical industry. COVID-19 vaccine shots are more popularly designated by the company that produced the vaccine rather than their proper names. “Moderna” and “Pfizer” are likely more recognizable than “Spikevax” or “Comirnaty”. While one executive from Moderna is quoted as favoring either “Spikevax” or “The Moderna COVID-19 Vaccine”, she notes that a unique and catchy name is still necessary.
Read more about how pharmaceuticals navigate these tricky trademark-naming waters in The Wall Street Journal.